Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. X:X | DOI: 10.5507/bp.2026.002

Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial

Vladimir Student Jr.1, Vaclav Repa1, 2, Jana Vrbkova3, Jan Vacek4
1 Department of Urology, University Hospital Olomouc, Czech Republic
2 Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
3 Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
4 Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic

Background: Chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent urological disorder with a significant impact on quality-of-life. This study assessed the effects of rectal administration of dual cannabidiol (CBD)/hyaluronic acid (HA)-based therapy in men with CP/CPPS.

Methods: A single-arm, open-label pilot trial on 16 men (24-49 years) with CP/CPPS (NIH Chronic Prostatitis Symptom Index [NIH-CPSI] >10, pain subscore ≥4). The participants self-administered rectal CANNEFF® suppositories containing CBD (100 mg) and HA (6.6 mg) as active ingredients, nightly for 30 days. Outcome measures included changes in NIH-CPSI total score, International Prostate Symptom Score (IPSS), and International Index of Erectile Function (IIEF-5). Safety and tolerability were also assessed.

Results: The median baseline NIH-CPSI score was 24.5 points (range 11, 39) decreasing to a median 20.0 (range 2, 26) at day 30 (P=0.003), with a median reduction of 7.0 points (range -20.0, 6.0). Symptom improvement was found in 81.3 % (13/16) of participants. The IPSS total score decreased from a median of 14.0 points (range 4, 32) to a median 12.0 (range 3, 18) (P=0.033), with voiding symptoms showing the largest improvement. The IIEF-5 score increased modestly but without statistical significance. No adverse events were reported.

Conclusions: The administration of the suppositories with CBD/HA action demonstrated potential symptom relief in CP/CPPS with a favourable tolerability profile. A more nuanced analysis of NIH-CPSI changes and IPSS and IIEF-5 data suggests a clinically meaningful benefit for most participants.

Keywords: prostatitis, chronic pelvic pain, cannabidiol, rectal delivery

Received: November 12, 2025; Revised: January 22, 2026; Accepted: January 23, 2026; Prepublished online: February 16, 2026 

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Franz J, Kieselbach K, Lahmann C, Gratzke C, Miernik A. Chronic Primary Pelvic Pain Syndrome in Men. Dtsch Arztebl Int 2023;120:508-18. Go to original source...
    2. Zhang J, Liang C, Shang X, Li H. Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Disease or Symptom? Current Perspectives on Diagnosis, Treatment, and Prognosis. Am J Mens Health 2020;14(1):1557988320903200. doi: 10.1177/1557988320903200 Go to original source... Go to PubMed...
    3. Franco JVA, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, Garrote V, Vietto V. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int 2020;125:490-96. Go to original source...
    4. Paulis G. Inflammatory mechanisms and oxidative stress in prostatitis: The possible role of antioxidant therapy. Res Rep Urol 2018;10:75-87. Go to original source...
    5. Piao JJ, Kim S, Shin D, Lee HJ, Jeon KH, Tian WJ, Hur KJ, Kang JS, Park HJ, Cha JY, Song A, Park SH, Rajasekaran M, Bae WJ, Yoon SK, Kim SW. Cannabidiol Alleviates Chronic Prostatitis and Chronic Pelvic Pain Syndrome via CB2 Receptor Activation and TRPV1 Desensitization. World J Mens Health 2024;43(1):228-38. doi: 10.5534/wjmh.230352 Go to original source... Go to PubMed...
    6. Liu Z, Martin JH. Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling. Br J Clin Pharmacol 2018;84:2483-87. Go to original source...
    7. Litwiniuk M, Krejner A, Grzela T. Hyaluronic Acid in Inflammation and Tissue Regeneration. Wounds 2016;28:78-88.
    8. Litwin MS, McNaughton-Collins M, Fowler Jr FJ, Nickel JC, Calhoun EA, Pontari MA, Alexander RB, Farrar JT, O'Leary MP, Alexander RB, Landis JR, Litwin MS, Nickel JC, O'Leary MP, Schaeffer AJ, Barry MJ, Bennett CL, Bushman W, Calhoun EA, Ceri H, Cifelli D, Duncan J, Farrar JT, Feldman HI, Hunter D, Jarvi K, Kusek J, Nadler RB, Nyberg LM, Ponniah S, Propert KJ, Ruggieri MR, Shoskes DA. The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure. J Urol 1999;162:369-75. Go to original source...
    9. Zámečník L. Sexual Dysfunction in patients with chronic prostatitis (chronic pelvic pain syndrome). Urol praxi 2005;1:23-25.
    10. Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RU, Pontari M, Shoskes DA, Litwin MS, Alexander RB, White PC, Berger R, Nadler R, O'Leary M, Men LL, Zeitlin S, Chuai S, Landis JR, Kusek JW, Nyberg LM, Schaeffer AJ. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 2008;59:2663-73. Go to original source...
    11. Altmäe S, Franasiak JM, Mändar R. The seminal microbiome in health and disease. Nat Rev Urol 2019;6:703-21. Go to original source...
    12. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, Blaivas JG, Wein AJ. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57. Go to original source...
    13. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30. Go to original source...
    14. Macchione N, Bernardini P, Piacentini I, Mangiarotti B, Del Nero A. Flower pollen extract in association with vitamins (Deprox 500®) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome: A comparative analysis of two different treatments. Antiinflamm Antiallergy Agents Med Chem 2019;18:151-61. Go to original source...
    15. Matsukawa Y, Naito Y, Funahashi Y, Ishida S, Fujita T, Tochigi K, Kato M, Gotoh M. Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study. Neurourol Urodyn 2020;39:1994-2002. Go to original source...
    16. Presicce F, Barrese F, Cantiani A, Filianoti A, Tuzzolo D, Di Palma P, Lauretti S, Brunori S, Martini M. Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study. Asian J Urol 2022;9:139-45. Go to original source...
    17. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999;54:960-63. Go to original source...
    18. Zhao WP, Zhang ZG, Li XD, Yu D, Rui XF, Li GH, Ding GQ. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazil J Med Biol Res 2009;42:963-67. Go to original source...
    19. Pyo JS, Cho WJ. Systematic Review and Meta-Analysis of Intravesical Hyaluronic Acid and Hyaluronic Acid/Chondroitin Sulfate Instillation for Interstitial Cystitis/Painful Bladder Syndrome. Cell Physiol Biochem 2016;39:1618-25. Go to original source...
    20. Cásedas G, Yarza-Sancho MD, López V. Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain. Pharmaceuticals 2024;17(11):1438. doi: 10.3390/ph17111438 Go to original source... Go to PubMed...
    21. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther 2017;175:133-50. Go to original source...
    22. Stecco C, Stern R, Porzionato A, MacChi V, Masiero S, Stecco A, De Caro R. Hyaluronan within fascia in the etiology of myofascial pain. Surg Radiol Anat 2011;33:891-96. Go to original source...
    23. Bonn-Miller MO, Pollack CV, Casarett D, Dart R, Elsohly M, Good L, Guzmán M, Hanuš L, Hill KP, Huestis MA, Marsh E, Sisley S, Skinner N, Spahr J, Vandrey R, Viscusi E, Ware MA, Abrams D. Priority Considerations for Medicinal Cannabis-Related Research. Cannabis Cannabinoid Res 2019;4:139-57. Go to original source...
    24. Kogan G, Šoltés L, Stern R, Gemeiner P. Hyaluronic acid: A natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett 2007;29:17-25. Go to original source...
    25. Atalay Ekiner S, Gęgotek A, Skrzydlewska E. The molecular activity of cannabidiol in the regulation of Nrf2 system interacting with NF-κB pathway under oxidative stress. Redox Biol 2022;57:102489. Go to original source...
    26. Dawidowicz AL, Olszowy-Tomczyk M, Typek R. CBG, CBD, Δ9-THC, CBN, CBGA, CBDA and Δ9-THCA as antioxidant agents and their intervention abilities in antioxidant action. Fitoterapia 2021;152:104915. doi: 10.1016/j.fitote.2021.104915 Go to original source... Go to PubMed...
    27. Vacek J, Vostalova J, Papouskova B, Skarupova D, Kos M, Kabelac M, Storch J. Antioxidant function of phytocannabinoids: Molecular basis of their stability and cytoprotective properties under UV-irradiation. Free Radic Biol Med 2021;164:258-70. Go to original source...
    28. Dehner J, Polanska HH, Petrlakova K, Zeljkovic SC, Beres T, Hendrych M, Storch J, Tarkowski P, Masarik M, Babula P, Vacek J. Safety assessment on CBD-rich hemp extract in sub-chronic cross-sex study with rats. Toxicol Appl Pharmacol 2025;495:117218. doi: 10.1016/j.taap.2024.117218 Go to original source... Go to PubMed...
    29. Polanska HH, Petrlakova K, Papouskova B, Hendrych M, Samadian A, Storch J, Babula P, Masarik M, Vacek J. Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol. Toxicology 2023;488:153460. doi: 10.1016/j.tox.2023.153460 Go to original source... Go to PubMed...
    30. Taylor C, Birch B. Cannabinoids in Urology. Which Benign Conditions Might They Be Appropriate to Treat: A Systematic Review. Urology 2021;148:8-25. Go to original source...
    31. Maeda K, Shigemura K, Fujisawa M. A review of current treatments for chronic prostatitis/chronic pelvic pain syndrome under the UPOINTS system. Int J Urol 2023;30:431-36. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return